Dishman Carbogen Amcis Share Price Today

Dishman Carbogen board to meet Oct 7 on NCD issuance and security change

Dishman Carbogen Amcis Ltd scheduled a board meeting for October 7, 2026. Agenda includes approving new NCD fundraising via private placement. Board will consider modification of security for ₹15 crore Tranche II NCDs. Existing ₹15 crore NCDs were allotted on September 28, 2026.

Dishman Carbogen Amcis shareholders approve all five AGM resolutions

Dishman Carbogen Amcis Limited passed all five resolutions at its 19th AGM held on September 30, 2026. Shareholders approved the adoption of standalone and consolidated financial statements for FY26. Re-appointment of Arpit J. Vyas as director and T R Chadha & Co. LLP as auditors secured majority support. Auditor re-appointment resolution saw 58,544 votes against, the highest dissent among all agenda items.

Dishman Carbogen Amcis unit passes US FDA inspection without issues

Dishman Carbogen Amcis subsidiary passed first US FDA inspection. Inspection at Vionnaz, Switzerland site concluded September 11, 2026. No Form 483 notice or observations raised by the regulator. Result underscores adherence to strict US market quality parameters.

Dishman Carbogen Amcis files FY26 BRSR report detailing ESG metrics

Export sales contributed 94.94% of total net sales in FY26. Total waste generation fell to 1,382.93 MT from 1,978.03 MT. Health and safety training coverage rose to 94.21%. Water withdrawal increased to 117,466 KL from 85,253 KL.

Dishman Carbogen Amcis schedules 19th AGM for September 30, 2026

Dishman Carbogen Amcis scheduled its 19th AGM for September 30, 2026. The meeting will be held via video conferencing at 3:00 pm IST. Compliance with MCA and SEBI circulars is mandated for the event.

Dishman Carbogen Amcis releases Q1FY27 earnings call transcript

Dishman Carbogen Amcis releases full transcript of Q1FY27 earnings call held on August 17, 2026. Revenue fell 4% YoY to INR 6,776 million due to deferred orders; EBITDA dropped to INR 600 million. Net debt stands at CHF 153.6 million; promoter entity to raise up to CHF 200 million via ECB at 4% interest. CDMO segment margin contracted to 6.3%; Marketable Molecules revenue rose to INR 1,432 million. Management expects single-digit group revenue growth in FY27 with improved margins in subsequent years.